Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream ...(hospitalization in non-ICUpatients with ...),Health

Date:7/15/2008

hospitalization in non-ICU patients with S. aureus, and in patients with blood cultures growing CoNS regardless of location with the hospital. PNA FISH diagnostic tests provide rapid results that enable us to optimize therapy, improve patient outcomes and reduce hospital costs," added Dr. Shoham.

"We are very excited to see the results from the Washington Hospital Center study. Not only do they show that rapid reporting of PNA FISH results can help significantly reduce unnecessary antibiotic use and improve patient care, but the rapid results also help to save lives," said Thais T. Johansen, President and CEO of AdvanDx. "If we extrapolate the data to the rest of the United States, PNA FISH has the potential of saving close to 23,000 patient lives, reducing 514,000 days of antibiotic use and saving $5 billion in hospital charges. In essence, implementing PNA FISH and rapidly reporting results to clinicians could be much more beneficial than the introduction of a new generation of antibiotics to treat patients with bloodstream infections," Johansen added.

About Bloodstream Infections

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The infection is detected when a culture of the patient's blood (i.e. a blood culture) turns positive with bacteria and yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

About PNA FISH(TM)

PNA FISH is an easy-to-use and highly sensitive and specific fluorescence in situ hybridization (FISH) assay that uses PNA (peptide nucleic acid) probes to target species specific ribosomal RNA (rRNA) in live bacteria and yeast. The unique properties of the non-charged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn fa
'/>"/>

SOURCE AdvanDx Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
2. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
5. Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU
6. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
7. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
8. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease